Regeneron Announces 2015 Winners of the Regeneron Prize for Creative Innovation

TARRYTOWN, N.Y., June 25, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the third annual Regeneron Prize for Creative Innovation, an award designed to acknowledge, reward and foster talented early-career biomedical scientists. This year, Regeneron awarded $155,000 in prize money to 10 awardees and two institutions.

"The winners of the Regeneron Prize for Creative Innovation are exemplary young scientists whose intelligence and unconventional thinking empower them to lead the next generation of biomedical discovery," said George D. Yancopoulos, M.D., Ph.D., President of Regeneron Laboratories and Chief Scientific Officer of Regeneron. "Regeneron is committed to fostering innovative scientific talent since we know these are the people capable of discovering and developing life-changing medical breakthroughs in the years to come."

Two winners of the Regeneron Prize will each receive a $50,000 cash prize. The institutions nominating the two winners will also receive a donation to support their seminar series. This year's winners are:

• Dr. Shruti Naik, The Rockefeller University, Regeneron Prize for Creative Innovation by a Postdoctoral Fellow
• Youjin Lee, Harvard University Graduate School of Arts and Sciences, Regeneron Prize for Creative Innovation by a Graduate Student

One additional Postdoctoral Fellow will be awarded an Honorable Mention and a cash prize of $10,000:

• Dr. Berenice A. Benayoun, Stanford University School of Medicine

Seven additional finalists will each be awarded $5,000.

Requests for applicants were distributed to academic institutions in November 2014. Each institution was asked to nominate two graduate students and two postdoctoral fellows. Each nominee's submission includes a proposal explaining the nominee's "dream" project in biomedical research, which offers insight into the nominee's creativity and ability to think independently as a scientist. Submissions also include a curriculum vitae, list of publications and a review of the nominee's productivity in their current laboratory.

"We are always impressed by the barrier-breaking approaches presented in the Regeneron Prize research proposals, and this year's winners, honorable mention and finalists once again demonstrated innovative thinking and passion," said Susan Croll, Ph.D., Regeneron scientist and Director of the Regeneron Postdoctoral Training Program. "We congratulate them and look forward to following their promising careers."

About Regeneron Pharmaceuticals, Inc.
Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, asthma, and atopic dermatitis. For additional information about the company, please visit www.regeneron.com.

Your Media Contact at Regeneron:
Alexandra Bowie, Tel. 914.847.3407
E-Mail: [email protected]

SOURCE Regeneron Pharmaceuticals, Inc.

Related Links

http://www.regeneron.com